This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): rVSV-EBOV Vaccine, BPSC1001, rVSVEBOV, V920, rVSV-ZEBOV-GP, V920 Ebola Vaccine
Description: NewLink is developing an Ebola vaccine.
NewLink Genetics and Merck
In November 2014, Merck and NewLink Genetics entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLink's investigational rVSV-EBOV (Ebola) vaccine candidate.
Under the terms of the agreement, Merck will be granted the exclusive rights to the rVSV-EBOV vaccine candidate as well as any follow-on products. The vaccine candidate is under an exclusive licensing arrangement with a wholly-owned subsidiary of NewLink Genetics. Under these license arrangements, the PHAC retains non-commercial rights pertaining to the vaccine candidate.
Partners: NewLink Genetics Corporation
Pink Sheet New EU Approvals
Pink Sheet New Filings At The EMA
Pink Sheet EU Accelerated Assessment Tracker
Additional information available to subscribers only: